Page 12 - தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation ACCESSWIRE 05 Aug 2021, 06:05 GMT+10 NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network ® (NCCN) added REZUROCK TM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (GVHD). The NCCN Guidelines in the United States now include REZUROCK with a Category 2A designation as a suggested systemic agent for steroid-refractory chronic GVHD. The rapid inclusion of REZUROCK into the NCCN guidelines shortly after full FDA approval validates the potential clinical impact of REZUROCK in this difficult-to-treat therapeutic landscape, said Harlan W. Waks

United statesHarlanw waksalExchange commissionKadmon holdings incDrug administrationNational comprehensive cancer networkKadmon holdingsNational comprehensive cancerPractice guidelinesHematopoietic cell transplantationPre transplant recipient evaluationGraft versus host diseaseBreakthrough therapyPriority reviewNew drug applicationReal time oncology review